05:52 AM EDT, 07/22/2025 (MT Newswires) -- Sanofi ( SNY ) said Tuesday it is acquiring UK-based Vicebio, for $1.15 billion with potential milestone payments of as much as $450 million based on development and regulatory achievements.

The transaction is expected to close in Q4 2025, the company said.

The deal brings an early-stage combination vaccine candidate targeting respiratory viruses and integrates Vicebio's proprietary 'Molecular Clamp' technology into Sanofi's ( SNY ) vaccine development platform, the company said.

The Molecular Clamp technology stabilizes viral proteins in their native conformation, enhancing immune recognition and allowing for faster development of fully liquid combination vaccines, it noted.

These vaccines can be stored at standard refrigeration temperatures (2-8 degrees Celsius), removing the need for freezing, which simplifies manufacturing and distribution, the company said.

Additionally, this format supports administration via prefilled syringes, improving safety and operational efficiency, Sanofi ( SNY ) added.

The company added this acquisition strengthens its position in the respiratory vaccine market, where it already has offerings for influenza and respiratory syncytial virus prevention.